Alterity Therapeutics has reported positive topline results from its open-label phase II clinical trial of lead drug ATH434, ...

ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms - ...

Praxis Precision Medicines' vormatrigine shows promise in epilepsy with 56.3% seizure reduction. Click here to find out why I ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis ...

Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the ...

SPG302, a Potential First-in-Class Synaptic Regenerative Therapy, Showed Progress in Cognitive Outcome Measures and a Favorable Safety Profile LOS ...

The first patient in the U.S. has been dosed with a novel radioactive medicine to treat advanced breast cancer as part of an international clinical trial.

All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months ...

Discover groundbreaking findings on oral gildeuretinol's impact on Stargardt disease at the ASRS 43rd Annual Meeting in Long ...

Mayo Clinic has treated the first person in the U.S. using a novel radioactive medicine for advanced breast cancer as part of an international multisite clinical trial.